| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7538116 | FABRE KRAMER | Treatment of sexual disorders |
Sep, 2025
(1 year, 4 months from now) | |
Exxua is owned by Fabre Kramer.
Exxua contains Gepirone Hydrochloride.
Exxua has a total of 1 drug patent out of which 0 drug patents have expired.
Exxua was authorised for market use on 22 September, 2023.
Exxua is available in tablet, extended release;oral dosage forms.
Exxua can be used as treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dysfunction adverse reactions.
Drug patent challenges can be filed against Exxua from 23 September, 2027.
The generics of Exxua are possible to be released after 22 September, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2028 |
Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient
NCE-1 date: 23 September, 2027
Market Authorisation Date: 22 September, 2023
Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...
Dosage: TABLET, EXTENDED RELEASE;ORAL
EXXUA family patents
